Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Feb 26, 2023; 15(2): 56-63
Published online Feb 26, 2023. doi: 10.4330/wjc.v15.i2.56
Published online Feb 26, 2023. doi: 10.4330/wjc.v15.i2.56
Utility of short-term telemetry heart rhythm monitoring and CHA2DS2-VASc stratification in patients presenting with suspected cerebrovascular accident
Tanzim Bhuiya, Taner Aydin, Bhakti Patel, Roman Zeltser, Amgad N Makaryus, Department of Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11553, United States
Sherif Roman, Department of Cardiology, St. Joseph’s University Medical Center, Paterson, NJ 07503, United States
Roman Zeltser, Amgad N Makaryus, Department of Cardiology, Nassau University Medical Center, East Meadow, NY 11554, United States
Author contributions: Aydin T, Zeltser R, Makaryus AN performed the research; Bhuiya T and Zeltser R performed the statistical analyses in the paper; Zeltser R and Makaryus AN designed the research and contributed to the analysis; Bhuiya T, Roman S, Aydin T, Patel B, Makaryus AN, wrote the paper; Zeltser R, and Makaryus AN supervised the report.
Institutional review board statement: The study was reviewed and approved by our institutional review board (IRB) as an expedited study (IRB#16-093).
Informed consent statement: This research was a retrospective anonymized evaluation and informed consent was not required for IRB approval of this expedited study. The information was recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects. Our IRB approval document is provided separately.
Conflict-of-interest statement: Authors of no conflict of interest to disclose.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at amakaryu@numc.edu.
STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Amgad N Makaryus, MD, FACC, Professor, Chairman, Department of Cardiology, Nassau University Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 2201 Hempstead Turnpike, East Meadow, NY 11554, United States. amakaryu@numc.edu
Received: September 26, 2022
Peer-review started: September 26, 2022
First decision: December 19, 2022
Revised: January 10, 2023
Accepted: February 7, 2023
Article in press: February 7, 2023
Published online: February 26, 2023
Processing time: 147 Days and 10.3 Hours
Peer-review started: September 26, 2022
First decision: December 19, 2022
Revised: January 10, 2023
Accepted: February 7, 2023
Article in press: February 7, 2023
Published online: February 26, 2023
Processing time: 147 Days and 10.3 Hours
Core Tip
Core Tip: Inpatient telemetry monitoring can be a costly resource in hospitals. Inappropriate use of this clinical tool only increases burgeoning healthcare costs both to the patient and the hospital. Atrial fibrillation is a risk factor for stroke which is why telemetry is indicated for 24-48 h after a cerebrovascular accident. However, telemetry for all patients for this short period of time can be non-diagnostic. Our study shows telemetry can be better utilized in patients with higher risk factors for atrial fibrillation as seen with higher CHA2DS2-VASc scores, and this stratification of telemetry monitoring may allow appropriate allocation and use for patients in whom benefit will be derived.